NCT07199010View on ClinicalTrials.gov

Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

Not yet recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions
Non-small Lung Cancer
Interventions
DRUG

Taletrectinib

Taletrectinib, 600mg, QD

Trial Locations (1)

200120

Shanghai East Hospital (The East Hospital Affiliated to Tongji University), Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY